All abstracts must be submitted, via the ESHRE website by Monday, 1 February 2027 at 11:59 (midday) Central European Time (CET).

There will be no extensions granted after the deadline. Abstracts must be submitted in English only.

IMPORTANT! By default the corresponding author will also be the presenting author in case the abstract is accepted for oral or poster presentation. By submitting an abstract for presentation at the Annual Meeting, you confirm that you will attend in-person in Stockholm and are sufficiently proficient in English to deliver your presentation and answer questions from the audience.

It is not allowed to change the corresponding/presenting author, nor is it allowed to make changes to the list of authors, the list of affiliations or the abstract itself after the corresponding/presenting author has received the outcome of the reviewing process. Ensure all details are accurate before submitting your abstract.

At submission, abstract must contain original material that (a) is unpublished, or has been accepted for publication but is not scheduled for publication more than three months before the Annual Meeting begins; and (b) has not previously been presented at an international meeting in reproductive medicine or reproductive science. Each presenting author may only submit one abstract.

The content of abstracts, posters, and oral presentations must not promote the business interests of any commercial company and must not include logos, commercial trademarks, or promotional messages. The name of a company, brand, or product must not appear in the title of any abstract, only generic names or neutral product descriptions may be used. The use of trade names is strongly discouraged. If they are mentioned, their use must be strictly limited to the Materials and Methods section.

The abstract submitter must ensure that the study type is accurately indicated. When the abstract reports on a randomised controlled trial (RCT), systematic review, or meta-analysis, a registration number is mandatory and must be provided in the designated field. For RCTs, prospective trial registration and prospective data collection are strongly recommended.
The abstract must include sufficient methodological detail to allow assessment of its scientific validity. This should include, where applicable, the number of participants, randomisation method, intervention(s), comparator(s), and primary outcome.
The Scientific Committee reserves the right to request additional information or data where necessary to verify the scientific validity and integrity of the submitted work and to remove abstracts with concerns on research integrity from the programme.

The submitting author is responsible for adding the co-authors. ESHRE will assume that the co-authors formally agreed to be listed.
Violation of the abstract submission rules can lead to exclusion for next annual meeting.

All abstracts will be reviewed anonymously, without the names and affiliations of the authors. Authors are requested to indicate their preference for oral and/or poster presentation on the abstract submission form. Abstracts submitted for oral/poster presentation, that are not selected for oral communication may be redirected to the poster sessions. The decisions of the selection committee are final. All accepted abstracts along with the index of authors will be published in an abstract book, which will be a supplement to the Human Reproduction Journals.

All abstracts will be reviewed and scored after which they will either be accepted for presentation or rejected. This process will take some time to complete and the results will be available no later than 25 April. At this time the submitter will be notified as to whether their abstract has been accepted or not.